Processa Pharmaceuticals Inc Stock Price, News & Analysis

Processa Pharmaceuticals has initiated its Phase 1b clinical trial for PCS6422, targeting patients with advanced, refractory gastrointestinal cancer. The first patient has been dosed in this multicenter study, which aims to assess the safety and pharmacokinetics of PCS6422 in combination with capecitabine. Interim results are expected by the end of 2021, with further studies planned for 2022 to establish maximum tolerated doses and biomarkers. The trial represents a significant step in developing therapies for patients with unmet needs in cancer treatment.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) will present at the "Zooming with LD Micro" virtual investor event on July 29, 2021, at 12:00 PM ET. Investors can register for the event on the company's website. Processa focuses on developing treatments for unmet medical needs and has a team experienced in over 30 FDA drug approvals. The company emphasizes improving patient survival and quality of life through its innovative products.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) will present at the Access to Giving Virtual Conference on July 14, 2021, at 10:30 a.m. ET. The presentation will be led by CEO Dr. David Young. The conference targets a range of companies and facilitates one-on-one meetings with qualified investors, who will donate to participate. Processa focuses on developing treatments for unmet medical needs, supported by a team with extensive FDA approval experience. For registration, visit here.

Processa Pharmaceuticals (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma (NASDAQ: OCUP) for RX-3117, an oral anticancer agent with FDA Orphan Designation for pancreatic cancer. The agreement grants Processa an exclusive worldwide license (excluding China) to develop and commercialize RX-3117. A Phase 2b trial is set to begin in 2022 to evaluate biomarker correlations and clinical effectiveness in patients with pancreatic and non-small cell lung cancer. The program aims to improve treatment options for patients needing better survival rates.

Processa Pharmaceuticals (NASDAQ: PCSA) announced it will join the Russell Microcap Index after the annual reconstitution on June 28, 2021. This inclusion signifies a substantial milestone for the company, potentially enhancing its visibility among investors and providing access to a wider investment base. The Russell indexes are crucial as they benchmark approximately $10.6 trillion in assets, suggesting that Processa's membership could attract more institutional investors. The company focuses on developing therapies for unmet medical needs, emphasizing treatments for various serious conditions.

Processa Pharmaceuticals (NASDAQ: PCSA) announced its participation in the LD Micro Virtual Investor Conference, scheduled for June 9, 2021, at 1:30 p.m. ET, Track 4. Management will present details about the company's pipeline aimed at improving survival and quality of life for patients with unmet medical needs. Current programs include PCS6422 for cancer treatments, PCS499 for ulcerative necrobiosis lipoidica, and PCS12852 for gastrointestinal issues. A live audio webcast of the event will be available for attendees.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two upcoming investor conferences. They will attend the Craig-Hallum Virtual Institutional Investor Conference on June 2, focusing on one-on-one meetings. Additionally, they will present at the Jefferies Virtual Healthcare Conference on June 4, from 2:00 to 2:25 PM EST, where one-on-one meetings will also be available. The company is committed to developing products to enhance survival and quality of life for patients with unmet medical needs.

Processa Pharmaceuticals (NASDAQ: PCSA) has dosed its first patient in a Phase 2B trial for PCS499, targeting ulcerations in patients with Necrobiosis Lipoidica (NL), a rare skin disease affecting collagen. The trial aims to assess the efficacy of PCS499 compared to a placebo. Approximately 30% of NL patients experience open ulcers that impair quality of life. Sian Bigora, Chief Development Officer, expressed optimism about the trial's potential impact on treatment options for this underserved condition.

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two investor conferences aimed at addressing unmet medical needs. The events include the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021 (on-demand presentations) and The Benchmark Company Healthcare House Call Virtual Conference on May 26, 2021 (one-on-one meetings). Processa focuses on developing treatments for conditions such as metastatic colorectal cancer, breast cancer, and GI motility disorders. The company aims to enhance patient survival and quality of life through existing clinical evidence.